Ontology highlight
ABSTRACT:
SUBMITTER: Hochhaus A
PROVIDER: S-EPMC4915803 | biostudies-literature | 2013 May
REPOSITORIES: biostudies-literature
Hochhaus Andreas A Saglio Giuseppe G Larson Richard A RA Kim Dong-Wook DW Etienne Gabriel G Rosti Gianantonio G De Souza Carmino C Kurokawa Mineo M Kalaycio Matt E ME Hoenekopp Albert A Fan Xiaolin X Shou Yaping Y Kantarjian Hagop M HM Hughes Timothy P TP
Blood 20130315 18
In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd phase 3 trial. At the 3-year data cutoff, mutations were detected in approximately twice as many patients (21) on imatinib 400 mg once daily as on nilotinib (11 patients each on nilotinib 300 mg twice daily and nilotinib 400 mg twice daily). The majority of m ...[more]